Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload

Liver International

Volumn 36, Issue 2, 2016, Pages 246-257

  Das, Subhash K ^a   Desaulniers, Jessica ^a   Dyck, Jason R B ^a   Kassiri, Zamaneh ^a   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Hepatic fibrosis; Inflammation; Iron overload; Lipid peroxidation; Oxidative stress; Resveratrol

Indexed keywords

CD71 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FERRITIN; GLUTATHIONE; GLUTATHIONE DISULFIDE; HEMOJUVELIN; HEPCIDIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRON; RESVERATROL; SIRTUIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR FKHR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, MOUSE; SIRT1 PROTEIN, MOUSE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DEACETYLATION; GENE EXPRESSION; GENETIC DISORDER; HEPATOSPLENOMEGALY; IRON METABOLISM; IRON OVERLOAD; LIPID PEROXIDATION; LIVER DISEASE; LIVER FIBROSIS; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PROTEIN ACETYLATION; PROTEIN DEPLETION; THERAPY EFFECT; ACETYLATION; ANIMAL; BIOLOGICAL MODEL; CHRONIC DISEASE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HEMOCHROMATOSIS; LIVER DISEASES; METABOLISM; TREATMENT OUTCOME;

ACETYLATION; ANIMALS; ANTIOXIDANTS; APOPTOSIS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FORKHEAD BOX PROTEIN O1; FORKHEAD TRANSCRIPTION FACTORS; HEMOCHROMATOSIS; IRON; IRON OVERLOAD; LIVER DISEASES; MICE; MODELS, GENETIC; OXIDATIVE STRESS; SIRTUIN 1; STILBENES; TREATMENT OUTCOME;

EID: 84955745628     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12893     Document Type: Article

References (52)

1. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999; 341: 1986-95.
2. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 2004; 350: 2383-97.
3. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med 2012; 366: 348-59.
4. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS, American Association for the Study of Liver D. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 328-43.
5. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77-82.
6. Abu Rajab M, Guerin L, Lee P, Brown KE. Iron overload secondary to cirrhosis: a mimic of hereditary haemochromatosis? Histopathology 2014; 65: 561-9.
7. Ko C, Siddaiah N, Berger J, et al. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int 2007; 27: 1394-401.
8. Pietrangelo A. Non-HFE hemochromatosis. Hepatology 2004; 39: 21-9.
9. Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC. A mouse model of juvenile hemochromatosis. J Clin Investig 2005; 115: 2187-91.
10. Trombini P, Paolini V, Pelucchi S, et al. Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. Liver Int 2011; 31: 994-1000.
11. Oudit GY, Trivieri MG, Khaper N, et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation 2004; 109: 1877-85.
12. Bacon BR, Park CH, Brittenham GM, O'Neill R, Tavill AS. Hepatic mitochondrial oxidative metabolism in rats with chronic dietary iron overload. Hepatology 1985; 5: 789-97.
13. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical-mediated process? Hepatology 1990; 11: 127-37.
14. Sale S, Verschoyle RD, Boocock D, et al. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3, 4, 5, 4'-tetramethoxystilbene. Br J Cancer 2004; 90: 736-44.
15. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-42.
16. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
17. Oudit GY, Sun H, Trivieri MG, et al. L-type Ca2 + channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003; 9: 1187-94.
18. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release 2012; 158: 182-93.
19. Wang W, McKinnie SM, Patel VB, et al. Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc 2013; 2: e000249.
20. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-5.
21. Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 2006; 1: 3159-65.
22. Mori J, Patel VB, Abo Alrob O, et al. Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation. Circ Heart Fail 2014; 7: 327-39.
23. Mehlem A, Hagberg CE, Muhl L, Eriksson U, Falkevall A. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat Protoc 2013; 8: 1149-54.
24. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-22.
25. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450: 712-6.
26. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005; 280: 17187-95.
27. Bacon BR, Britton RS, O'Neill R. Effects of vitamin E deficiency on hepatic mitochondrial lipid peroxidation and oxidative metabolism in rats with chronic dietary iron overload. Hepatology 1989; 9: 398-404.
28. Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology 2015; 61: 1066-79.
29. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18: 1028-40.
30. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256-62.
31. Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-19.
32. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769-78.
33. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221-30.
34. Pietrangelo A, Gualdi R, Casalgrandi G, Montosi G, Ventura E. Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents. J Clin Invest 1995; 95: 1824-31.
35. Carthew P, Edwards RE, Smith AG, Dorman B, Francis JE. Rapid induction of hepatic fibrosis in the gerbil after the parenteral administration of iron-dextran complex. Hepatology 1991; 13: 534-9.
36. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007; 46: 1291-301.
37. Sebastiani G, Gkouvatsos K, Maffettone C, et al. Accelerated CCl4-induced liver fibrosis in Hjv-/- mice, associated with an oxidative burst and precocious profibrogenic gene expression. PLoS ONE 2011; 6: e25138.
38. Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 2005; 115: 2180-6.
39. Angelucci E, Baronciani D, Lucarelli G, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 1995; 89: 757-61.
40. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110: 971-7.
41. Brown KE, Dennery PA, Ridnour LA, et al. Effect of iron overload and dietary fat on indices of oxidative stress and hepatic fibrogenesis in rats. Liver Int 2003; 23: 232-42.
42. Matsumoto M, Pocai A, Rossetti L, Depinho RA, Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab 2007; 6: 208-16.
43. Perdomini M, Belbellaa B, Monassier L, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia. Nat Med 2014; 20: 542-7.
44. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-69.
45. Yoshiji H, Kuriyama S, Miyamoto Y, et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000; 32: 1248-54.
46. Nagai H, Matsumaru K, Feng G, Kaplowitz N. Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes. Hepatology 2002; 36: 55-64.
47. Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 2014; 147: 765-83 e4.
48. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
49. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009; 50: 1294-306.
50. Kawada N, Seki S, Inoue M, Kuroki T. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998; 27: 1265-74.
51. Fleming RE, Holden CC, Tomatsu S, et al. Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis. Proc Natl Acad Sci USA 2001; 98: 2707-11.
52. Walkin L, Herrick SE, Summers A, et al. The role of mouse strain differences in the susceptibility to fibrosis: a systematic review. Fibrogenesis Tissue Repair 2013; 6: 18.